Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Bioorg Med Chem Lett. 2008 Sep 12;18(22):5941–5944. doi: 10.1016/j.bmcl.2008.09.043

Figure 4.

Figure 4

HeLa cells expressing Cyclin B1 constructs were treated with Shield-1 or mock-treated following release from cell cycle arrest and incubated for the indicated periods of time. Cells were then analyzed by flow cytometry for DNA content. (A) Analysis of Shield-1-treated (red) and mock-treated (black) cells expressing L106P-Δ65Cyclin B1 at 0h, 8h, and 24h post-release from arrest. (B) Analysis of Shield-1-treated (faded colors) and mock-treated (solid colors) cells expressing L106P-Cyclin B1 (red) or L106P-Δ65Cyclin B1 (blue) 12 hours after release from arrest. The experiment was performed in triplicate (± s.d).

HHS Vulnerability Disclosure